Study shows ‘obesity paradox’ does not exist: waist-to-height ratio is a better indicator of outcomes in patients with heart failure than BMI. New research has debunked the idea that there is an “obesity paradox,” whereby patients with heart failure who are overweight or obese are thought to be l
Results from DELIVER made dapagliflozin the third SGLT2 inhibitor to benefit patients with HFpEF, cementing a new, ejection fraction-agnostic management approach.